CARY, N.C. — October 29, 2025 — Leads & Copy — Heron Therapeutics, Inc. (Nasdaq: HRTX) has appointed Thomas Cusack to its Board of Directors, effective October 27, 2025. Cusack’s expertise spans corporate finance, investment management, and governance.
Cusack’s appointment stems from a Cooperation Agreement with Rubric Capital Management LP, dated August 8, 2025. His 20+ years in investment management include a role as Managing Director at Starboard Value LP, where he focused on evaluating investments and improving corporate governance.
Heron’s CEO, Craig Collard, expressed confidence in Cusack’s ability to contribute to the company’s momentum.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Ira Duarte, Executive Vice President, Chief Financial Officer, can be reached at iduarte@herontx.com or 858-251-4400.
Source: Heron Therapeutics, Inc.
